OncoImmunology
Volume 5, 2016 - Issue 5
Open access
2,161
Views
68
CrossRef citations to date
0
Altmetric
Original Research
Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
Ioannis KarydisCancer Sciences Academic Unit, University of Southampton, Southampton, United KingdomCorrespondence[email protected]
, Pui Ying ChanDepartment of Medical Oncology, St Bartholomew's Hospital, London
, Matthew WheaterMedical Oncology, University Hospital Southampton, Southampton, United Kingdom
, Edurne ArriolaMedical Oncology, University Hospital Southampton, Southampton, United Kingdom
, Peter W. SzlosarekDepartment of Medical Oncology, St Bartholomew's Hospital, London;Barts Cancer Institute, Queen Mary University of London, London
& Christian H. OttensmeierCancer Sciences Academic Unit, University of Southampton, Southampton, United Kingdom
Article: e1143997
|
Received 02 Oct 2015, Accepted 14 Jan 2016, Published online: 31 May 2016
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.